Device Trial Radar · NCT07172464
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 9, 2025
Primary completion
Aug 2027
Study completion Feb 2032
Sponsor
- Lead sponsor
- Recross Cardio, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- MCRA
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is: • Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO. Participants will: * Undergo the procedure to implant the P3 Occluder System, if deemed appropriate. * Visit their doctor at 1 month, 3 months, 6 months, 1 year and 5 years after the procedure for follow up exams. * Answer a phone call from study staff at 2 years, 3 years and 4 years after the procedure to answer a survey.
Conditions
- PFO
- PFO - Patent Foramen Ovale
- Cryptogenic Stroke
- Patent Foramen Ovale
- PFO-associated Stroke
Interventions
Recross P3 Occluder (P3O) SystemDevice
The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety Endpoint - Rate of Major Adverse Cardiovascular Events (MACE)Time frame: 30 days
- Primary Performance Endpoint - Effective PFO ClosureTime frame: 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
UCLA
Los Angeles, California · Recruiting
The Cardiac and Vascular Institute
Gainsville, Florida · Recruiting
Tufts Medical Center
Boston, Massachusetts · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.